Anti-SMAD4 (DPC4) antibody [B-8] (STJ16101862)
SPECIFICATIONS
ClonalityMonoclonal
HostMouse
ConjugationUnconjugated
IsotypeIgG1
ImmunogenAmino acid 1-552 representing full length Smad4 of human origin
General Information
| Short Description | Mouse monoclonal anti-SMAD4 (DPC4) for use in IHC-P in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | IHC-P |
| Host | Mouse |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Clone ID | B-8 |
| Isotype | IgG1 |
| Conjugation | Unconjugated |
| Purification | Purified |
| Dilution Range | IHC-P 1:200-1:400 |
| Formulation | Purified antibody fraction from mouse anti-serum with 0.2% BSA and 15mM sodium azide |
| Storage Instruction | Store at 2-8°C for up to 1-year, upon receipt. |
Target Information
| Immunogen | Amino acid 1-552 representing full length Smad4 of human origin |
Additional Info
| Background | Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as SMADs. Upon ligand binding, the receptors of the TGF-Beta family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD 1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4) , also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80% of cases of pancreatic adenocarcinoma, but rarely in endometrial (0%) , colorectal (0%) , ovarian (3%) , lung (0%) , breast (2%) adenocarcinomas, and malignant melanoma (4%). SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma. Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival than SMAD4 negative patients. Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, or in 50 mM Tris buffer pH9.5, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections. Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended. Control tissue Pacreatic adenocarcinoma. Staining Nuclear. |
Information sourced from Uniprot.org